Pharmafile Logo

News and Press Releases

ADOA PROGRAM – PRESENTATION AT NANOS 2026

PYC is a precision medicine company dedicated to changing the lives of patients with genetic diseases who have no treatment options available One of PYC’s clinical-stage programs is an investigational...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 24, 2026

PYC Therapeutics
info@pyctx.com
6 Verdun Street, Nedlands, Western Australia 6009

Emmes Coordinates Groundbreaking Stem-Cell Ophthalmology Trial

18 February 2026 -- Maryland, US -- Emmes, a full-service, global Clinical Research Organization (CRO) dedicated to supporting the advancement of public health and biopharmaceutical innovation – in collaboration with the UC Davis Eye...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: February 18, 2026

Emmes
401 North Washington Street Suite 700 Rockville, MD 20850

Stratasys Digital Anatomy Technology Powers First 3D-Printed Eyelid Surgery Training Models in Europe

Addion and the University of Innsbruck advance surgical education with life-like anatomical models that enhance the skill sets of medical professionals and improve patient outcomes 18 November 2025 -- Minnesota,...

Category: Biotechnology, Other, Pharmaceutical
Posted: November 18, 2025

Stratasys
5995 Opus Parkway Minnetonka, MN 55343

Santen Launches SETANEO Ophthalmic Solution 0.002% in Japan for the Treatment of Glaucoma and Ocular Hypertension

23 October 2025 -- Osaka, Japan -- Santen Pharmaceutical Co., Ltd announced today that it launched SETANEO Ophthalmic Solution 0.002% (generic name: sepetaprost; hereafter the product) in Japan, for the...

Category: Drug Delivery, Other, Pharmaceutical
Posted: October 23, 2025

Santen
Grand Front Osaka Tower A, 4-20 Ofuka-cho, Kita-ku, Osaka 530-8552, Japan

Horus Pharma announces strategic Agreement to commercialize Formycon’s Aflibercept Biosimilar FYB203 under the brand name Baiama across Key European Markets including its Home Market France

23 October 2025 -- Nice, France -- Horus Pharma, the second largest independent ophthalmological laboratory in France and a leading player in Europe, today announced that it has entered into...

Category: Logistics, Other, Pharmaceutical
Posted: October 23, 2025

Horus Pharma
contact@horus-pharma.fr
22 allée Camille MUFFAT - Inedi 5 06200 Nice

ANI Pharmaceuticals Announces NEW DAY Clinical Trial Results to be Presented in Late-Breaking Oral Presentation at the American Academy of Ophthalmology 2025 Meeting

Presentation at AAO 2025 part of ongoing NEW DAY data dissemination at medical meetings 16 October 2025 -- New Jersey, US -- ANI Pharmaceuticals, Inc today announced that results from...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: October 16, 2025

ANI Pharmaceuticals
210 Main Street West Baudette, MN 56623

Peer Reviewed Publication Provides Evidence for Iron Dysregulation as a Driver of Dry AMD/GA and the Potential of Transferrin to Restore Iron Balance, Reinforcing PulseSight’s Therapeutic Strategy for PST-611

14 October 2025 -- Paris, France -- PulseSight Therapeutics, a clinical stage ophthalmology biotech company developing disruptive non-viral vectorized therapies with minimally-invasive delivery technology welcomes the publication of new data...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: October 14, 2025

PulseSight Therapeutics
contact@pulsesight.com
PariSanté Campus, 2-10 Rue d’Oradour-sur-Glane, 75015 Paris

OKYO Pharma Announces Registration Pathway with 100 Patient Multi-Center Clinical Trial of Urcosimod in Neuropathic Corneal Pain

22 September 2025 -- London, UK and New York, US -- OKYO Pharma Limited, an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod to treat neuropathic corneal pain (NCP), an ocular...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: September 22, 2025

OKYO Pharma
info@okyopharma.com
OKYO Pharma Floor 4, 14/15 Conduit St London W1S 2XJ

Ocugen, Inc. and Kwangdong Pharmaceutical Co., Ltd. Complete License Agreement of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea

Upfront fees and near-term development milestone payments totaling up to $7.5 million Potential sales milestones of $180 million or more in first 10 years of commercialization Royalties equaling 25% of...

Category: Biotechnology, Drug Discovery, Other, Pharmaceutical
Posted: September 15, 2025

Ocugen
11 Great Valley Parkway Malvern, PA 19355

PulseSight Therapeutics Provides New Insights into the Role of Iron and Transferrin in AMD, Supporting its PST-611 Vectorized Therapy for Dry AMD/Geographic Atrophy at EURETINA 2025

4 September 2025 -- Paris, France -- PulseSight Therapeutics, an ophthalmology biotech company developing disruptive non-viral vectorized therapies with minimally-invasive delivery technology announces that its CSO, Thierry Bordet Ph.D., will...

Category: Clinical Trials, Drug Delivery, Drug Discovery, Other, Pharmaceutical
Posted: September 4, 2025

Fidia Farmaceutici enters the UK market with the acquisition of Altacor Ltd

Marking another significant milestone in its ongoing international expansion, the Company enters the rapidly-growing UK ophthalmology market, a key therapeutic area for the Group 3 September 2025 -- Abano Terme,...

Category: Biotechnology, Drug Discovery, Other, Pharmaceutical
Posted: September 3, 2025

Fidia Farmaceutici
Via Ponte della Fabbrica 3/A – 35031 Abano Terme (PD) – Italy

Rockville-Based CRO Emmes Groups’ OptymEdge launch the first dedicated ophthalmology clinical trial platform at ARVO

Phase 1 will see new eSource technology launched at event, marking OptymEdge’s evolution into a full-service ophthalmic research partner 14 May 2025 -- Wisconsin, US -- OptymEdge – part of...

Category: Biotechnology, Clinical Trials, Other, Pharmaceutical
Posted: May 14, 2025

OptymEdge
11414 West Park Place, Suite 202, Milwaukee, WI 53224, US

FDA Grants OKYO Pharma Fast Track Designation to Urcosimod for Neuropathic Corneal Pain

1 May 2025 -- London, UK and New York, US -- OKYO Pharma Limited, an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod (formerly called OK-101) to treat NCP, an ocular...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: May 1, 2025

OKYO Pharma
info@okyopharma.com
OKYO Pharma Floor 4, 14/15 Conduit St London W1S 2XJ

Innovent Dosed First Participant in Phase 3 Clinical Study of IBI354 (Novel HER2 ADC) for Platinum-resistant Ovarian Cancer

24 March 2025 -- California, US and Suzhou, China -- Innovent Biologics, Inc, a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology,...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 24, 2025

Innovent
pr@innoventbio.com
1 Kingdom Street, Suite 445-446, London, W2 6BD, United Kingdom

PulseSight Therapeutics announces the initiation of the clinical plan of PST-611, Transferrin Vectorized Therapy for dry AMD/Geographic Atrophy

14 January 2025 -- Paris, France -- PulseSight Therapeutics SAS, an ophthalmology biotech company developing disruptive non-viral vectorized therapies with minimally-invasive delivery technology, today announces it has submitted a Clinical...

Category: Biotechnology, Clinical Trials, Drug Discovery, Pharmaceutical
Posted: January 14, 2025

PulseSight Therapeutics
contact@pulsesight.com
PariSanté Campus, 2-10 Rue d’Oradour-sur-Glane, 75015 Paris